Compare BBAR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | NVAX |
|---|---|---|
| Founded | 1886 | 1987 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 1.6B |
| IPO Year | 1997 | 1996 |
| Metric | BBAR | NVAX |
|---|---|---|
| Price | $13.30 | $9.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $17.00 | $11.33 |
| AVG Volume (30 Days) | 672.3K | ★ 4.4M |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $13.00 | N/A |
| P/E Ratio | $26.78 | ★ $3.77 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $7.76 | $5.01 |
| 52 Week High | $23.10 | $11.85 |
| Indicator | BBAR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 46.76 |
| Support Level | $7.87 | $9.14 |
| Resistance Level | $17.36 | $10.42 |
| Average True Range (ATR) | 0.86 | 0.60 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 27.99 | 16.52 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.